Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.

Purpose: This study characterized the effects of hepatic impairment on the pharmacokinetics and safety of glecaprevir and pibrentasvir, two direct-acting antivirals used for treatment of chronic HCV infection.Methods: HCV-negative subjects with normal hepatic function, or with mild (Child-Pugh [CP]-...

Descripción completa

Detalles Bibliográficos

Publicado en:	European Journal of Clinical Pharmacology Vol. 75; no. 2; pp. 217 - 227
Autores principales:	Kosloski, Matthew P., Liu, Wei, Wang, Haoyu, Pugatch, David, Mensa, Federico J., Gane, Edward, Lawitz, Eric, Marbury, Thomas C., Preston, Richard A., Kort, Jens
Formato:	research tables/charts Journal Article
Publicado:	Springer Nature Feb2019
Acceso en línea:	Ver este registro en EBSCOhost